Biopulse International Inc.

AuthorCole, Kelleigh
PositionBrief Article

Provo -- California-based Biopulse International Inc., has entered into an agreement with BRIGHAM YOUNG UNIVERSITY to acquire exclusive rights in the United States, Canada, Europe and Australia to a new cancer diagnostic technology. This test measures blood levels of TK1 (Thymidine Kinase 1) a marker that has shown high correlation to cancer activity and cancer stages. The test kit will be targeted for...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT